AbbVie Inc. (LON:0QCV)

London flag London · Delayed Price · Currency is GBP · Price in USD
227.16
-1.11 (-0.49%)
At close: Dec 5, 2025
28.16%
Market Cap 299.90B
Revenue (ttm) 44.37B
Net Income (ttm) 1.75B
Shares Out n/a
EPS (ttm) 0.98
PE Ratio 171.69
Forward PE 16.52
Dividend 5.03 (3.42%)
Ex-Dividend Date Oct 15, 2025
Volume 5,009
Average Volume 25,895
Open 230.50
Previous Close 228.27
Day's Range 225.07 - 229.36
52-Week Range 146.95 - 244.49
Beta 0.35
RSI 48.68
Earnings Date Jan 30, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange London Stock Exchange
Ticker Symbol 0QCV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.